{"nctId":"NCT01947855","briefTitle":"Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2013-09"},"conditions":["Diabetes Mellitus, Type 2"],"count":60,"armGroups":[{"label":"Empagliflozin low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin","Drug: Placebo"]},{"label":"Empagliflozin high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Empagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Empagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Empagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Diagnosis of type 2 diabetes mellitus prior to informed consent\n* Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:\n\n  * drug-naÃ¯ve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,\n  * pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)\n* Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)\n\n  * for patients without antidiabetic therapy : HbA1c \\>=7.0 to =\\<10.0%\n  * for patients with one oral antidiabetic drug : HbA1c \\>=7.0 to =\\<9.5%\n\nExclusion criteria:\n\n* Uncontrolled hyperglycaemia with a glucose level \\>240 mg/dL (\\>13.3 mmol/L)\n* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \\<60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)\n* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent\n* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment","description":"The primary endpoint is the change in AUC1-4h for postprandial plasma glucose based on meal tolerance test from baseline after 28 days of treatment. Baseline refers to the last observation prior to administration of randomised study medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.07","spread":"13.89"},{"groupId":"OG001","value":"-103.56","spread":"14.24"},{"groupId":"OG002","value":"-122.94","spread":"14.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Nasopharyngitis","Anal inflammation","Rash pruritic","Pollakiuria","Bartholinitis"]}}}